By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
.
An antibiotic is cefuroxime. It functions by halting the development of the bacterial protective coating, which is necessary for bacteria to survive in the human body.
A beta-lactamase inhibitor, clavulanic acid prevents the action of bacterially generated enzymes that inactivate Cefuroxime combined with CLAVULANIC ACID Belonging to the class of drugs known as antibiotics that are used to treat a variety of bacterial diseases, including sinusitis, gonorrhoeic, Lyme disease, septicemia, pharyngitis/tonsillitis, otitis media, and ear infections.
For the management and treatment of bacterial infections, notably those caused by beta-lactamase-producing bacteria, clavulanic acid is a drug that can be used with amoxicillin. It belongs to the group of drugs called beta-lactamase inhibitors.
The Global cefuroxime clavulanic acid market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The present invention relates to pharmaceutical formulations including cefuroxime acetyl and clavulanic acid for use in treating and preventing infections caused by gramme positive and gramme negative bacteria in the upper respiratory tract, such as otitis media, sinusitis, tonsillitis, and pharyngitis;
Lower respiratory tract infections, such as pyelonephritis, cystitis, and urethritis; and skin and soft tissue infections, such as furan To prevent bacterial resistance and give even greater antibacterial resistance, tablet formulations are also being developed that combine a beta-lactam group cephalosporin antibiotic, like cefuroxime acetyl, and a beta-lactam inhibitor, like clavulanic acid.
The solubility and stability issues with cefuroxime acetyl formulations, however, are more pronounced in tablet formulations containing cefuroxime acetyl and clavulanic acid in the prior art because clavulanic acid has a significant propensity for moisture absorption because of its hygroscopic nature.
The current invention relates to formulations that contain cefuroxime acetyl and clavulanic acid and are created in film-coated tablet form. These formulations are distinguished by the fact that they contain at least one cellulose-based diluent and that the weight ratio of cefuroxime acetyl to diluent is between 1:5 and 5:1.
In another aspect, the present invention relates to formulations made into film-coated tablets that contain clavulanic acid and cefuroxime acetyl. It is distinguished by having at least one cellulose-based diluent and a ratio of cefuroxime acetyl to diluent that is preferably between 1:2 and 4:1 by weight.
